CSIMarket
 


Neubase Therapeutics inc   (NBSE)
Other Ticker:  
 

Neubase Therapeutics Inc 's Leverage Ratio

NBSE's quarterly Leverage Ratio and Total Liabilities, Equity growth


In Spite of the repayements of liabilities of -14.46%, in III Quarter 2023 ,Leverage Ratio deteriorated to 1.04 is above the company's typical Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the third quarter 2023, 300 other companies have achieved lower Leverage Ratio than Neubase Therapeutics Inc in the III Quarter 2023. While Leverage Ratio total ranking has deteriorated compared to the second quarter 2023 from 1389 to 1785 .

Explain Leverage Ratio?
Who are NBSE Customers?
What are NBSE´s Total Liabilities?


NBSE Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
I. Quarter
(Sep 30 2022)
IV. Quarter
Y / Y Equity Change -60.6 % -70.53 % -73.28 % -69.77 % -3.12 %
Y / Y Total Liabilities Change -0.18 % 4.17 % -30.57 % -18.62 % 168.74 %
Leverage Ratio MRQ 1.04 0.99 0.49 0.4 0.41
NBSE's Total Ranking # 1785 # 1389 # 1100 # 405 # 987
Seq. Equity Change -18.76 % -22.16 % -20.72 % -21.42 % -39.23 %
Seq. Total Liabilities Change -14.46 % 58.15 % -4.74 % -22.55 % -10.73 %



Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 301
Healthcare Sector # 601
Overall Market # 1785


Leverage Ratio Statistics
High Average Low
13.67 0.62 0.01
(Jun 30 2012)   (Jun 30 2014)




Financial Statements
Neubase Therapeutics Inc 's Equity $ 9 Millions Visit NBSE's Balance sheet
Neubase Therapeutics Inc 's Total Liabilities $ 9 Millions Visit NBSE's Balance sheet
Source of NBSE's Sales Visit NBSE's Sales by Geography


Cumulative Neubase Therapeutics Inc 's Leverage Ratio

NBSE's Leverage Ratio for the trailling 12 Months

NBSE Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
I. Quarter
(Sep 30 2022)
IV. Quarter
Y / Y Equity TTM Growth -60.6 % -70.53 % -73.28 % -69.77 % -3.12 %
Y / Y Total Liabilities TTM Growth -0.18 % 4.17 % -30.57 % -18.62 % 168.74 %
Leverage Ratio TTM 0.66 0.52 0.37 0.28 0.22
Total Ranking TTM # 1793 # 1848 # 5 # 92 # 552
Seq. Equity TTM Growth -18.76 % -22.16 % -20.72 % -21.42 % -39.23 %
Seq. Total Liabilities TTM Growth -14.46 % 58.15 % -4.74 % -22.55 % -10.73 %


On the trailing twelve months basis Despite of the repayements of liabilities of -14.46% in the trailing twelve months ending in III Quarter 2023, Leverage Ratio improved to 0.66, a new company high.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 306, during the past 12 months, other companies have achieved lower Leverage Ratio than Neubase Therapeutics Inc . While Leverage Ratio total ranking has improved so far to 1793, from total ranking in previous 12 month period at 1848.

Explain Leverage Ratio?
Who are NBSE Customers?
What are NBSE´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 307
Healthcare Sector # 608
Within the Market # 1793


trailing twelve months Leverage Ratio Statistics
High Average Low
0.66 0.21 0.06
(Sep 30 2023)   (Mar 31 2019)




Companies with similar Leverage Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Equity
Harrow Inc   2.79 $ 210.308  Millions$ 75.402  Millions
Kineta Inc   2.77 $ 7.991  Millions$ 2.889  Millions
Marinus Pharmaceuticals Inc   2.65 $ 144.368  Millions$ 54.537  Millions
Journey Medical Corporation  2.62 $ 45.447  Millions$ 17.374  Millions
Durect Corp  2.55 $ 36.752  Millions$ 14.406  Millions
Apellis Pharmaceuticals Inc   2.52 $ 585.945  Millions$ 232.271  Millions
Proqr Therapeutics N v   2.33 $ 108.072  Millions$ 46.357  Millions
Gossamer Bio Inc   2.33 $ 243.308  Millions$ 104.617  Millions
Phibro Animal Health Corporation  2.27 $ 620.465  Millions$ 273.069  Millions
Uniqure N v   2.21 $ 594.878  Millions$ 268.784  Millions
Biovie Inc   2.15 $ 16.212  Millions$ 7.548  Millions
Bristol myers Squibb Company  2.14 $ 62,265.000  Millions$ 29,062.000  Millions
Casi Pharmaceuticals inc   2.11 $ 51.103  Millions$ 24.165  Millions
G1 Therapeutics Inc   2.09 $ 90.075  Millions$ 43.022  Millions
Milestone Pharmaceuticals inc   2.06 $ 58.612  Millions$ 28.504  Millions
Cerevel Therapeutics Holdings Inc   2.01 $ 549.000  Millions$ 272.962  Millions
Abeona Therapeutics Inc   2.00 $ 44.049  Millions$ 22.038  Millions
Travere Therapeutics Inc   1.98 $ 553.084  Millions$ 279.766  Millions
Maravai Lifesciences Holdings Inc   1.96 $ 1,748.259  Millions$ 892.281  Millions
Jazz Pharmaceuticals Plc  1.92 $ 6,684.082  Millions$ 3,489.373  Millions
Cyclacel Pharmaceuticals Inc   1.91 $ 8.200  Millions$ 4.297  Millions
Syros Pharmaceuticals Inc   1.87 $ 67.800  Millions$ 36.302  Millions
Ibio inc   1.85 $ 24.469  Millions$ 13.209  Millions
Veru Inc   1.85 $ 32.813  Millions$ 17.783  Millions
Catalyst Biosciences Inc   1.83 $ 6.447  Millions$ 3.517  Millions
Clene Inc   1.82 $ 39.027  Millions$ 21.406  Millions
Zoetis Inc   1.78 $ 9,028.000  Millions$ 5,074.000  Millions
Nektar Therapeutics  1.77 $ 282.876  Millions$ 159.368  Millions
Cv Sciences Inc   1.74 $ 6.061  Millions$ 3.479  Millions
Blue Water Biotech Inc   1.72 $ 17.645  Millions$ 10.236  Millions

Date modified: 2023-11-12T06:08:56+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com